Copyright
©The Author(s) 2020.
World J Gastroenterol. May 14, 2020; 26(18): 2221-2231
Published online May 14, 2020. doi: 10.3748/wjg.v26.i18.2221
Published online May 14, 2020. doi: 10.3748/wjg.v26.i18.2221
Table 1 Baseline characteristics of study patients
Parameter | n (%) |
Age (yr) | 57 (IQR 50–65) |
Male | 133 (71) |
Current smoker | 70 (37) |
Co morbidities | |
IHD | 16 (9) |
DM | 64 (34) |
CCF | 16 (9) |
Previous CVA | 15 (8) |
COPD | 14 (7) |
Non-HCC malignancy | 20 (11) |
CKD | 39 (21) |
Ascites | 138 (73) |
Aetiology of cirrhosis | |
Alcohol | 117 (62) |
HBV | 6 (3) |
HCV | 59 (31) |
NASH | 37 (20) |
PSC | 6 (3) |
AIH | 4 (2) |
PBC | 1 (1) |
Other | 11 (6) |
Child Pugh score | 11 (IQR 9-12) |
CPA | 3 (2) |
CPB | 39 (21) |
CPC | 120 (64) |
Unknown | 26 (14) |
MELD | 25 (IQR 18-31) |
Hepatic encephalopathy | |
Grade 1 | 22 (5) |
Grade 2 | 93 (23) |
Grade 3 | 38 (57) |
Grade 4 | 9 (14) |
Unknown grade | 26 |
Previous episode of encephalopathy | 75 |
Median duration of encephalopathy (d) | 7 (IQR 2-9) |
Table 2 Baseline laboratory parameters
Parameters | mean ± SD |
Haemoglobin (g/L) | 90 ± 20 |
Platelet (× 109/L) | 86.1 ± 64 |
White cell count (× 109/L ) | 8 ± 6 |
Bilirubin (µmol/L) | 151 ± 168 |
Albumin (g/L) | 25 ± 7 |
ALT (U/L) | 135 ± 468 |
ALP (U/L) | 166 ± 106 |
GGT (U/L) | 154 ± 262 |
INR | 2.1 ± 1.0 |
Urea (mmol/L) | 11 ± 7 |
Creatinine (micromol/L) | 161 ± 138 |
Sodium (mmol/L) | 133 ± 7 |
Potassium (mmol/L) | 4.5 ± 1.0 |
Table 3 Precipitating factors for hepatic encephalopathy (alone or in combination with other factors)
Precipitating factors | n (%) |
Infection including SBP | 81 (43) |
Gastrointestinal bleeding | 31 (16) |
Constipation (opiate-induced) | 10 (5) |
Constipation (not opiate induced) | 25 (13) |
Benzodiazepine use | 10 (5) |
Noncompliance to regular medications | 29 (15) |
Electrolyte imbalance | 27 (14) |
Other | 24 (13) |
Unknown | 15 (8) |
Table 4 Hazard ratio for the different variables investigated by univariate analysis and multivariate analysis as possible prognostic factors in 188 cirrhotic patients presenting with hepatic encephalopathy and commenced on rifaximin
Variable | Univariate hazard ratio using cox regression (95%CI)1 | Multivariate hazard ratio (95%CI)1 |
Age | 1.014 (0.99, 1.03) | |
Sex (male vs female) | 1.087 (0.75, 1.58) | |
Aetiology of cirrhosis2 | ||
HBV infection | 0.76 (0.28, 2.05) | |
HCV infection | 0.62 (0.42, 0.91)a | |
Alcohol | 0.92 (0.65, 1.30) | |
Precipitating factors2 | ||
Gastrointestinal bleed | 0.75 (0.46, 1.22) | |
Infection | 1.49 (1.03, 2.15)a | |
Diuretic therapy | 1.47 (0.94, 2.32) | |
Constipation | 1.19 (0.73, 1.95) | |
Ascites at the time of HE2 | 1.11 (0.77, 1.59) | |
Maximal grade of HE (grade 3 and 4 vs grade 1 and 2) | 0.80 (0.53, 1.21) | |
Serum values3 | ||
Bilirubin | 1.001 (1, 1.002)a | |
ALT | 1 (0.99, 1.003) | |
GGT | 1 (1, 1) | |
Albumin | 0.97 (0.95, 1.002) | |
Urea | 1.05 (1.02, 1.09)a | |
Creatinine | 1.001 (1, 1.002)a | |
Sodium | 0.99 (0 .97, 1.03) | |
Potassium | 1.16 (0.96, 1.40) | |
INR | 1.5 (1.21, 1.85)a | 1.27 (1.04, 1.54)a |
Hb | 0.98 (0.97, 1.01) | |
WCC | 1.06 (1.02, 1.10)a | |
Plt | 1.00 (0.99, 1.01) | |
Child Pugh Score (C vs A/B) | 1.57 ( 1.02, 2.41)a | |
MELD | 1.03 (1.01, 1.06)a | |
MELD (≥ 15 vs ≤ 15) | 2.41 ( 1.20. 4.85)a | 2.17 (1.07, 4.43)a |
- Citation: Bohra A, Worland T, Hui S, Terbah R, Farrell A, Robertson M. Prognostic significance of hepatic encephalopathy in patients with cirrhosis treated with current standards of care. World J Gastroenterol 2020; 26(18): 2221-2231
- URL: https://www.wjgnet.com/1007-9327/full/v26/i18/2221.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i18.2221